Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Other Gross PP&E Adjustments (2020 - 2023)

Historic Other Gross PP&E Adjustments for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $4.2 million.

  • Candel Therapeutics' Other Gross PP&E Adjustments rose 1007.27% to $4.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was $4.2 million, marking a year-over-year increase of 1007.27%. This contributed to the annual value of $3.6 million for FY2022, which is 789.79% up from last year.
  • Candel Therapeutics' Other Gross PP&E Adjustments amounted to $4.2 million in Q3 2023, which was up 1007.27% from $4.3 million recorded in Q2 2023.
  • Candel Therapeutics' 5-year Other Gross PP&E Adjustments high stood at $4.3 million for Q2 2023, and its period low was $2.3 million during Q4 2020.
  • Its 4-year average for Other Gross PP&E Adjustments is $3.6 million, with a median of $3.7 million in 2021.
  • In the last 5 years, Candel Therapeutics' Other Gross PP&E Adjustments surged by 4797.89% in 2021 and then crashed by 905.9% in 2022.
  • Candel Therapeutics' Other Gross PP&E Adjustments (Quarter) stood at $2.3 million in 2020, then surged by 47.98% to $3.4 million in 2021, then increased by 7.9% to $3.6 million in 2022, then grew by 16.68% to $4.2 million in 2023.
  • Its Other Gross PP&E Adjustments stands at $4.2 million for Q3 2023, versus $4.3 million for Q2 2023 and $3.9 million for Q1 2023.